Latest Share Options News

Invion Limited posted a $8.8 million loss for FY25, marking a 56.5% increase, while advancing clinical trials and securing fresh capital. The biotech faces a going concern warning amid ongoing development and funding challenges.

Basin Energy has agreed to acquire NeoDys Limited, gaining a dominant uranium and rare earth portfolio in northwest Queensland, fully funded to commence drilling in late 2025.

Pure Foods Tasmania has secured a $400,000 investment from entrepreneurs Jon Kontopos and Matthew Abrahams as part of a broader $750,000 capital raising effort, reinforcing confidence in the company’s turnaround plan ahead of its upcoming shareholder vote.

Biome Australia Limited reports its first profitable year since 2018, driven by a 41.6% revenue increase and significant international growth.

COG Financial Services reported a modest 1% revenue increase and stable underlying profits for FY25, driven by strong Novated Leasing growth and key acquisitions, while cutting its final dividend and shifting focus to EBITDA.

COG Financial Services Limited reported a 23% increase in net profit after tax to $18.8 million for FY2025, driven by growth in novated leasing and asset management segments. The company declared a fully franked final dividend of 3.0 cents per share, reflecting a strategic shift towards broking capabilities.

Matrix Composites & Engineering Ltd posted a 12.1% revenue decline to $74.77 million for FY25, reporting a net loss of $2.2 million as subdued drilling buoyancy markets weighed on results despite strong growth in subsea buoyancy products.

AUCyber Limited reported a 112% revenue increase to $23 million in FY25, driven by acquisitions and cybersecurity growth, despite a $37.6 million net loss largely due to impairment charges. The company’s strategic pivot under 5G Networks’ majority ownership signals a renewed focus on sovereign cloud and AI-enhanced security services.

Beforepay Group Limited reported a robust 74.5% increase in net profit after tax to $6.7 million for FY25, driven by growth in its core Pay Advance business, the launch of a Personal Loan product, and expansion of its AI-powered credit analytics division, Carrington Labs, in the US.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

PolyNovo Limited reported a robust 28.9% increase in group sales to A$118.6 million for FY25, alongside a 151% surge in net profit after tax to A$13.2 million, driven by strong U.S. growth and key regulatory approvals.

Alfabs Australia Limited reported a robust 242% increase in net profit for FY2025 despite a slight dip in revenue, underpinned by strong operational performance and major contract deliveries. The company declared a final dividend, signaling confidence in its financial position.